🔎 Trials Near Me

Utama › Limfoma Burkitt › Illinois › Chicago

Kajian klinikal Limfoma Burkitt di Chicago, IL

14 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Mengambil pesertaFasa 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
366 Days – 46 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Mengambil pesertaFasa 3
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • dan 1 lagi
Umur 18 hingga 39 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03150693

Blinatumomab Consolidation in Real World

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Northwestern University, Chicago
  • The University of Chicago, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Mengambil pesertaFasa 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Mengambil pesertaFasa 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Mengambil pesertaFasa 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 1 hingga 30 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mengambil pesertaFasa 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Mengambil pesertaFasa 2
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Umur 7 hingga 25 · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Mengambil pesertaFasa 1/2
  • Research Site, Chicago
Umur 12 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Mengambil pesertaFasa 1/2
  • Research Site, Chicago
Umur 12 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Mengambil pesertaFasa 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 18 hingga 54 · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Mengambil pesertaFasa 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Nov 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Mengambil pesertaFasa 1/2
  • University of Chicago, Chicago
Umur 15 hingga 50 · Semua jantina · Dikemas kini 9 Sep 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

Mengambil peserta
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Umur 18 hingga 50 · Semua jantina · Dikemas kini 19 Jun 2025 · NCT06785324

Kajian Limfoma Burkitt di bandar lain

Kajian lain di Chicago

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.